Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 211Triple Negative Breast Neoplasms 32Stomach Neoplasms 32Inflammatory Breast Neoplasms 21Esophageal Neoplasms 16Carcinoma, Hepatocellular 15Lymphoma, Large B-Cell, Diffuse 9Sarcoma 8Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 5Liver Neoplasms 5Breast Neoplasms, Male 5Adenocarcinoma Of Esophagus 5Ovarian Neoplasms 4Lymphoma 4Testicular Neoplasms 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Hemangiosarcoma 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplastic Cells, Circulating 2

Interventions

apatinib 9Paclitaxel 9Capecitabine 7Oxaliplatin 6camrelizumab 5Cisplatin 5S 1 (combination) 4Fluorouracil 3Docetaxel 3130-nm albumin-bound paclitaxel 3titanium silicide 2Leucovorin 2Drug Therapy 2vorolanib 1trifluridine tipiracil drug combination 1tipiracil 1spartalizumab 1rucaparib 1relatlimab 1raltitrexed 1pazopanib 1olaparib 1lobaplatin 1linrodostat 1ezogabine 1endostar protein 1durvalumab 1dacomitinib 1capivasertib 1Trifluridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Gastric Cancer × Epirubicin × Clear all
NCT00743964 2010-01-15

Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)

Samsung Medical Center

Phase 2 Completed
91 enrolled
Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡